Charles River Laboratories International announced the opening of another RightSourceSM facility, and first in the United Kingdom, UK, which will provide services to the Stevenage advanced therapies biocluster. “Traditional testing paradigms place the burden on the client-from developing processes and upfront lab setup costs to bearing responsibility for regulatory compliance,” said Ian Wyllie, Director Operations, RightSource, Charles River. “The RightSource business model significantly reduces that burden. By leveraging our flexible testing platform and robust scientific expertise, clients gain direct access to industry-leading biologics testing, located next to their manufacturing operations.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on CRL:
- Charles River price target lowered to $275 from $280 at Wells Fargo
- Charles River price target lowered to $225 from $255 at Guggenheim
- Charles River price target lowered to $256 from $267 at Baird
- Charles River price target lowered to $230 from $245 at BofA
- Charles River’s updated targets below consensus expectations, says UBS